ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,201.60
1.67%
S&P ASX All Technology
3,829.30
1.67%
Brent Oil
72.885
0.23%
US Dollar vs AUD
1.59767
-0.11%
Bitcoin
94,957.02
-0.17%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Humacyte Inc (HUMA) Share Price

Humacyte Inc

Humacyte Inc (HUMA)

NASDAQ
4.64
1.18
(34.10%)
Closed 23 December 8:00AM
Delayed by 15 minutes
4.75
0.11
(2.37%)
After Hours: 11:59AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
4.75
Bid
3.67
Offer
6.10
Volume
74,297,235
4.45 Day's Range 6.77
2.48 52 Week Range 9.97
Market Cap
597.833M
Previous Close
3.46
Open
5.8349
Last Trade
5
@
4.75
Last Trade Time
Financial Volume
US$ 369,453,091
VWAP
4.9726
Average Volume (3m)
3,093,427
Shares Outstanding
125,859,496
Dividend Yield
-
PE Ratio
-12.45
Earnings Per Share (EPS)
-0.88
Revenue
-
Net Profit
-110.78M

About Humacyte Inc

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases,... Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.humacyte.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Humacyte Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker HUMA. The last closing price for Humacyte was US$3.46. Over the last year, Humacyte shares have traded in a share price range of US$ 2.48 to US$ 9.97.

Humacyte currently has 125,859,496 shares in issue. The market capitalisation of Humacyte is US$435.47 million. Humacyte has a price to earnings ratio (PE ratio) of -12.45.

Ask ADVFN Intelligence (AI)

Humacyte (HUMA) Options Flow Summary

HUMA Options Flow

Overall Flow

Bullish

Net Premium

155k

Calls / Puts

160.00%

Buys / Sells

300.00%

OTM / ITM

62.50%

Sweeps Ratio

7.69%

HUMA Latest News

More News

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The...

19 December 2024
PR Newswire (US)

Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA PR Newswire NEW YORK, Dec. 16, 2024 NEW YORK, Dec. 16, 2024...

16 December 2024
PR Newswire (US)

Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Dec. 12, 2024 NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The...

12 December 2024
PR Newswire (US)

The Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA

The Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA PR Newswire NEW YORK, Dec. 9, 2024 NEW YORK, Dec...

09 December 2024
PR Newswire (US)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit - HUMA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit - HUMA PR Newswire NEW YORK, Dec. 5, 2024 NEW YORK, Dec. 5, 2024 /PRNewswire/...

05 December 2024
PR Newswire (US)

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders PR Newswire NEW YORK, Nov. 22, 2024 NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The...

22 November 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

04 September 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 September 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

04 September 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

30 August 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6315.29126213594.124.863.3732818583.76038976CS
40.368.200455580874.395.033.3726975784.20336904CS
12-0.78-14.10488245935.536.343.3730934274.94673248CS
26-0.99-17.24738675965.749.793.3731719415.85840234CS
521.7859.93265993272.979.972.4823506455.61807892CS
156-4.02-45.83808437868.779.971.9610717365.15793611CS
260-5.25-52.51017.451.9610163775.41542078CS

HUMA - Frequently Asked Questions (FAQ)

What is the current Humacyte share price?
The current share price of Humacyte is US$ 4.75
How many Humacyte shares are in issue?
Humacyte has 125,859,496 shares in issue
What is the market cap of Humacyte?
The market capitalisation of Humacyte is USD 435.47M
What is the 1 year trading range for Humacyte share price?
Humacyte has traded in the range of US$ 2.48 to US$ 9.97 during the past year
What is the PE ratio of Humacyte?
The price to earnings ratio of Humacyte is -12.45
What is the reporting currency for Humacyte?
Humacyte reports financial results in USD
What is the latest annual profit for Humacyte?
The latest annual profit of Humacyte is USD -110.78M
What is the registered address of Humacyte?
The registered address for Humacyte is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Humacyte website address?
The website address for Humacyte is www.humacyte.com
Which industry sector does Humacyte operate in?
Humacyte operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
120.01M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
76.64M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
33.95M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.61k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
120.4M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
277.63M

HUMA Discussion

View Posts
Monksdream Monksdream 1 day ago
HUMA under $5

[color=red][/color]
👍️0
threebabiesbusy threebabiesbusy 2 days ago
Wainwright analyst Vernon Bernardino raised the firm's price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb ...
👍️0
threebabiesbusy threebabiesbusy 2 days ago
Let's push through the $4.80 wall!
👍️0
threebabiesbusy threebabiesbusy 3 days ago
awww so you're out. Looks difficult for afternoon move up
👍️0
threebabiesbusy threebabiesbusy 3 days ago
We're trading substantially below days VWAP....
👍️0
threebabiesbusy threebabiesbusy 3 days ago
Lunch time pull back. Do you anticipate afternoon trend back up? Or do we call it one and done!
👍️0
TrendTrade2016 TrendTrade2016 3 days ago
EXITED ON THAT PUSH BOTTOM BOUNCE
👍️0
Tiger Money Tiger Money 3 days ago
Love having you back.  You are one of the smartest traders out there.  Unfortunately you like to be mean to less intelligent people 😝.  Anyways, how far do you think this could run?  Thanks
👍️0
FooBarAndGrill FooBarAndGrill 3 days ago
Now, reality bites.
Cash and time to ramp up.
Will vascular surgeons switch from the old and familiar?
TBD.
👍️0
TrendTrade2016 TrendTrade2016 3 days ago
HUMA READY TO RUN AGAIN
👍️0
Tiger Money Tiger Money 3 days ago
Finally!
👍️ 1
FooBarAndGrill FooBarAndGrill 3 days ago
Approved
https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue
👍️ 1
FooBarAndGrill FooBarAndGrill 2 weeks ago
Today is Dec 9th. Dec 9th marks 10 months since HUMA's PDUFA application.
FDA has performance goals. For regular PDUFA applications the goal is 90% within 10 months.
FDA performance goals: https://www.fda.gov/media/151712/download
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
I don't know of any. But you can roll your own using eg. Amazon Transcribe.
👍️0
tm100 tm100 2 weeks ago
Is there a transcript available anywhere? Have not had any success finding a transcript
👍️0
Tiger Money Tiger Money 2 weeks ago
Good news that they don't pull the plug.  This will be accepted by RFK less than a month in office 
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
The FDA is the wall. She can't say anything.
Adding that FDA has performance goals which, in this case, are not being met.
👍️0
Tiger Money Tiger Money 3 weeks ago
You say ok.  So everything is moving forward with the fda still?  Thanks 
👍️0
FooBarAndGrill FooBarAndGrill 3 weeks ago
Webcast OK. Direct questions and direct answers.
👍️0
FooBarAndGrill FooBarAndGrill 3 weeks ago
Supplemental BLA. Discussed during webcast.
Replay is up. https://investors.humacyte.com/news-events/events-and-presentations
👍️0
Tiger Money Tiger Money 3 weeks ago
If they are selling for any other reason than to keep it below 5%, there will be a ton of lawsuits....
👍️0
FooBarAndGrill FooBarAndGrill 3 weeks ago
Stonewalled.
The family sold with the excuse to reduce below 5% holding. That's no excuse at all. They're still insiders and know exactly what's up.
👍️0
Tiger Money Tiger Money 3 weeks ago
Crazy
👍️0
FooBarAndGrill FooBarAndGrill 4 weeks ago
$HUMA It's all in the family:
Mr. Dougan is married to Dr. Niklason and Mr. Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Mr. Dougan may be deemed to share beneficial ownership of the securities held of record by Dr. Niklason, The Niklason Living Trust and Ayabudge LLC.
👍️0
Tiger Money Tiger Money 1 month ago
Great color!  Time for the fda to let this run
👍️0
roadkilll roadkilll 2 months ago
Department of Defense's priority designation is a strong tell about the future of civilian use.
"Humacyte is currently evaluating the HAV in a phase 2/3 clinical trial in vascular trauma for use as a vascular replacement to restore blood flow to a limb when saphenous veins or synthetic grafts are not feasible. The HAV has received priority designation for the treatment of vascular trauma by the United States Secretary of Defense."
Sept 22, 2023 article
.
after approval expect a quick order from DOD
👍️0
roadkilll roadkilll 2 months ago
A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints. RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
.
FDA has awarded Humacyte for two indications.
👍️0
Monksdream Monksdream 2 months ago
HUMA under $6
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Has ANYTHING changed?
August 9, 2024 “We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review.”
👍️0
Tiger Money Tiger Money 3 months ago
This company has a lot going for it, that is for sure
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
Humacyte up today on genuinely positive SA piece.
https://seekingalpha.com/article/4722917-humacyte-navigating-the-fda-uncertainty-and-atevs-potential
👍️0
Tiger Money Tiger Money 3 months ago
Very nice!
👍️0
Sirpeter Sirpeter 3 months ago
Wynn for the win...my horse is coming in
👍️0
Tiger Money Tiger Money 3 months ago
Great to hear from you. I bought a bunch of calls for 5 cents here for he t week expiry. I can only hope Christmas comes early…
👍️0
Sirpeter Sirpeter 3 months ago
How are ya bud...been busy...Sept sucks for stocks...only holding some WYNN calls until interest rate cuts on the 18th...have to remember to ck in once in here a while lol...hope all is good with you...talk again soon
👍️0
Tiger Money Tiger Money 3 months ago
You still around? I have a feeling go time could be soon but fda always has em all by the balls ….
👍️0
Tiger Money Tiger Money 3 months ago
Likey or dislikey? Just waiting on fda. Tech is there, proven and safe. A lot of limbs/lives saved in Ukraine because of humacyte
👍️0
Monksdream Monksdream 4 months ago
HUMA under $7

👍️0
Tiger Money Tiger Money 4 months ago
Their product is amazing. Will help so many people
👍️0
Tiger Money Tiger Money 4 months ago
Great stuff and that is what I see too. Thanks!
👍️0
Sirpeter Sirpeter 4 months ago
I sold my options here and bought shares...they're cheap
👍️0
Stern is Bald Stern is Bald 4 months ago
Very promising stock and the is an opportunity to buy the dip big time..
👍️0
Tiger Money Tiger Money 4 months ago
Ok, now that is cleared up. In all seriousness, looking for your thoughts on huma . Thanks and appreciate and hope we can work together to make some $
👍️0
Stern is Bald Stern is Bald 4 months ago
Just nonsensical jibberish about deep state blah blah blah… either wat i am 90% of tuning out the knuckleheads on this site… glad you put it out there like that easier to know not to take anything from you very seriously…
👍️0
Tiger Money Tiger Money 4 months ago
Not sure I have been called Jesus before especially since I’m not Spanish.
👍️0
Tiger Money Tiger Money 4 months ago
What? You didn’t like the coup?
👍️0
Stern is Bald Stern is Bald 4 months ago
Man are you dumb jesus…
👍️0
Sirpeter Sirpeter 4 months ago
Think the dumbacrats are here to stay...will see
👍️0
Tiger Money Tiger Money 4 months ago
Worse, they are owned by the deep state. The same deep state/military industrial complex that has completely taken over the Democratic Party.
👍️0
Sirpeter Sirpeter 4 months ago
Too politcal?
👍️0

Your Recent History

NASDAQ
HUMA
Humacyte
BIT
P18294
Bnp Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads